Emergence of YMDD mutant hepatitis B virus after allogeneic stem cell transplantation from a HBsAG-positive donor during lamivudine prophylaxis.
Lee
Yen-Chien
YC
Section of Hematology/oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Young
Kung-Chia
KC
Su
Wu-Chou
WC
Tsao
Chao-Jung
CJ
Chen
Tsai-Yun
TY
D000914:Antibodies, Viral / Q000097:blood; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006509:Hepatitis B / Q000517:prevention & control / Q000635:transmission*; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000150:complications / Q000628:therapy; D009154:Mutation; D011292:Premedication / Q000379:methods; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014019:Tissue Donors; D014184:Transplantation, Homologous
D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine